ATE428790T1 - Verbessertes system zur regulation der transgenexpression - Google Patents

Verbessertes system zur regulation der transgenexpression

Info

Publication number
ATE428790T1
ATE428790T1 AT01977218T AT01977218T ATE428790T1 AT E428790 T1 ATE428790 T1 AT E428790T1 AT 01977218 T AT01977218 T AT 01977218T AT 01977218 T AT01977218 T AT 01977218T AT E428790 T1 ATE428790 T1 AT E428790T1
Authority
AT
Austria
Prior art keywords
improved system
transgene expression
regulating transgene
regulating
inducer
Prior art date
Application number
AT01977218T
Other languages
English (en)
Inventor
Ronald Abruzzese
Vidya Mehta
Jeffrey Nordstrom
Jason G Fewell
Original Assignee
Genetronics Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetronics Inc, Baylor College Medicine filed Critical Genetronics Inc
Application granted granted Critical
Publication of ATE428790T1 publication Critical patent/ATE428790T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Eye Examination Apparatus (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Mushroom Cultivation (AREA)
  • Paper (AREA)
AT01977218T 2000-09-25 2001-09-25 Verbessertes system zur regulation der transgenexpression ATE428790T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23503000P 2000-09-25 2000-09-25
US26078101P 2001-01-10 2001-01-10
US27828101P 2001-03-23 2001-03-23
PCT/US2001/030305 WO2002024899A2 (en) 2000-09-25 2001-09-25 Improved system for regulation of transgene expression

Publications (1)

Publication Number Publication Date
ATE428790T1 true ATE428790T1 (de) 2009-05-15

Family

ID=27398677

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977218T ATE428790T1 (de) 2000-09-25 2001-09-25 Verbessertes system zur regulation der transgenexpression

Country Status (7)

Country Link
US (1) US7579326B2 (de)
EP (1) EP1326969B1 (de)
AT (1) ATE428790T1 (de)
AU (1) AU2001296354A1 (de)
CA (1) CA2423093C (de)
DE (1) DE60138404D1 (de)
WO (1) WO2002024899A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066149A2 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
US9453219B2 (en) * 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
US7935788B2 (en) * 2004-10-04 2011-05-03 National Research Council Of Canada Reverse cumate repressor mutant
EP1797186B1 (de) * 2004-10-04 2016-05-25 National Research Council Of Canada Expressionssystem, dessen komponenten und verwendungsverfahren
JP2008545639A (ja) * 2005-05-19 2008-12-18 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 改善された調節発現系を用いる疾患の治療
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
DOP2006000117A (es) * 2005-05-19 2007-11-30 Schering Ag Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
CN101330830B (zh) 2005-10-18 2016-01-20 国家犹太健康中心 条件无限增殖化长期干细胞和制备和使用所述细胞的方法
WO2007134906A1 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Interferon-beta gene therapy using an improved, regulated expression system
WO2007134907A2 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US9169462B2 (en) * 2008-07-21 2015-10-27 Taiga Biotechnologies, Inc. Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
EP2318435B1 (de) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Myc-modulatoren, verfahren zu ihrer verwendung und verfahren zur identifikation von mitteln zur myc-modulierung
AU2009302804B2 (en) * 2008-10-08 2015-07-02 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
WO2012125652A2 (en) * 2011-03-14 2012-09-20 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
EP2877189B1 (de) 2012-07-20 2021-01-06 Taiga Biotechnologies, Inc. Verbesserte rekonstitution und autorekonstitution des hämatopoietischen kompartments
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US20190233825A1 (en) * 2015-06-26 2019-08-01 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
EP3368054A4 (de) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Regulierbare expression unter verwendung des adeno-assoziierten virus (aav)
US20170198363A1 (en) * 2015-12-28 2017-07-13 Colorado State University Research Foundation Compositions and methods for detection of small molecules
EP3411483B1 (de) * 2016-02-05 2022-07-06 PolyGene AG Glucocorticoid-basiertes genregulationssystem
EP3235516B1 (de) 2016-04-22 2019-06-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Regulierbarer adeno-assoziierter virus (aav)-vektor
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
CA3045017A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11780902B1 (en) 2018-07-20 2023-10-10 Colorado State University Research Foundation Receptor/histidine kinase fusion constructs and uses thereof
WO2021173647A1 (en) * 2020-02-25 2021-09-02 University Of Massachusetts Inducible single aav system and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS62171696A (ja) 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
AU633045B2 (en) 1988-12-23 1993-01-21 Salk Institute For Biological Studies, The Receptor transcription-repression activity compositions and methods
EP0473716A4 (en) 1989-05-26 1992-09-09 The Salk Institute For Biological Studies Dominant negative members of the steroid/thyroid superfamily of receptors
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US6416998B1 (en) * 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
CZ286046B6 (cs) 1993-04-29 1999-12-15 Abbott Laboratories Přípravky na bázi analogů erythropoietinu a způsoby jejich přípravy a farmaceutické přípravky s jejich obsahem
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
AU6908998A (en) * 1996-10-29 1998-05-22 Baylor College Of Medicine Modified glucocorticoid receptors, glucocorticoid receptors/progesterone receptors hybrids
CA2297490A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
GB9718591D0 (en) * 1997-09-03 1997-11-05 Zeneca Ltd Methods
EP1042000A4 (de) * 1997-12-23 2005-03-02 Cell Genesys Inc Transfer von einer mehrzahl von genen in zellen unter verwendung mehrerer adeno-assoziierter viraler vektoren
GB9817660D0 (en) 1998-08-13 1998-10-07 Angeletti P Ist Richerche Bio Adenoviral vectors encoding erythropoietin and their use in gene therapy
WO2000031286A1 (en) * 1998-11-20 2000-06-02 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
WO2001066149A2 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use

Also Published As

Publication number Publication date
EP1326969B1 (de) 2009-04-15
CA2423093C (en) 2013-09-17
WO2002024899A3 (en) 2002-12-12
CA2423093A1 (en) 2002-03-28
US7579326B2 (en) 2009-08-25
EP1326969A2 (de) 2003-07-16
AU2001296354A1 (en) 2002-04-02
US20030220286A1 (en) 2003-11-27
DE60138404D1 (de) 2009-05-28
WO2002024899A2 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
ATE428790T1 (de) Verbessertes system zur regulation der transgenexpression
WO2018209320A8 (en) APTAZYME-INCORPORATED GUIDED RNA FOR USE WITH CRISPR-CAS9 IN THE GENOME EDITION AND TRANSCRIPTIONAL ACTIVATION
DE602005015994D1 (de) siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
ATE430589T1 (de) Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
DK1334200T3 (da) Multipelt inducerbart genreguleringssystem
DK1354034T3 (da) Transgene transchromosomale gnavere til fremstilling af humane antistoffer
ATE395826T1 (de) Verwendung von 3-(2,4,6-trimethylphenyl)-4- neopentylcarbonyloxy-5,5-tetramethylen- dihydrofuran-2-on zur bekämpfung von psylliden
HRP20050705B1 (hr) Ekspresijski vektor koji sadrži promotor mcmv ie2
BRPI0413024A (pt) sistema de expressão de gene de inseto, promotor, vetor, inseto e, método para estabelecer compatibilidade de um promotor com uma espécie
ATE390125T1 (de) Formulierung für einen dosierinhalator unter verwendung von hydro-fluoro-alkanen als treibstoffe
ATE360701T1 (de) Putrescin-n-methyltransferasepromotor
DE50111331D1 (de) Neue verwendung von proteinhydrolysaten
CA2429679A1 (en) Hd3a gene inducing flowering of plant and utilization thereof
ATE368847T1 (de) Vorrichtung zur kontrolle von material
DE60128830D1 (de) Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren
ATE543502T1 (de) Allomon-abstossungsmittel zur kontrolle von arachnidae
DK1210446T3 (da) Modificeret ubiquitin-regulatorisk system
DE60029748D1 (de) Biologische bekämpfung von nematoden
DE50214936D1 (de) Verwendung des adenoviralen e2-late-promotors
ATE273394T1 (de) Wirts-vektor-systeme zur phosphatregulierten überproduktion von polypeptiden in bacillus
DE50303586D1 (de) Methylthiophencarboxanilide
ATE371734T1 (de) Neue oligoribonucleotid-derivate zur gezielten hemmung der genexpression
ATE335087T1 (de) Globaler regulator, verwendet zur erhöhung der synthese von aromatischen substanzen
TW200700130A (en) Message character string output system and controlling method of the same and information memory media
ATE307201T1 (de) Srcr domäne-enthaltendes protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties